Iovance Biotherapeutics Financial Ratios
NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Iovance Biotherapeutics ratio analysis
Iovance Biotherapeutics earned a net margin of -148.4% in FY 2025, up from -226.8% a year earlier. Gross margin was 34.3% compared with a median of 28.1% over the prior 2 years. Return on equity reached -56.0%, meaning Iovance Biotherapeutics generated -0.56 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Iovance Biotherapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 0.00 | 0.01 | 1.61 | — | — | — | — | — | — | — |
| Price / book | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Gross margin | 34.3% | 43.2% | 13.1% | — | — | — | — | — | — | — |
| Operating margin | -153.1% | -240.9% | -38,735.0% | — | — | — | — | — | — | — |
| Net margin | -148.4% | -226.8% | -37,345.4% | — | — | — | — | — | — | — |
| Free cash flow margin | -127.6% | -221.9% | -32,305.3% | — | — | — | — | — | — | — |
| Return on equity (ROE) | -56.0% | -52.4% | -76.0% | -79.2% | -55.1% | -39.5% | -66.1% | -26.5% | -63.3% | -31.7% |
| Return on assets (ROA) | -42.8% | -40.9% | -56.9% | -59.6% | -44.0% | -33.8% | -57.3% | -25.7% | -59.3% | -30.8% |
| Debt / equity | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Current ratio | 3.20 | 3.74 | 2.79 | 5.24 | 5.69 | 11.59 | 8.10 | 33.02 | 15.56 | 34.12 |
| Revenue growth | 60.6% | 13,699.0% | — | — | — | — | — | — | — | — |